Loading...
Market
Which COVID-19 vaccine targeting the KP.2 variant will be most administered in the US by December 31, 2024?
2
Resolution / Starting Odds
Pfizer-BioNTech • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Administration data can be verified through public health reports and vaccination statistics
Story
Health Canada Approves Moderna's Updated COVID-19 Vaccine Targeting KP.2 Variant for Ages Six Months and Older
Sep 17, 2024, 03:06 PM
Health Canada has approved Moderna's updated COVID-19 vaccine targeting the KP.2 variant of SARS-CoV-2 for ages six months and older. This approval follows the FDA's authorization of three updated vaccines, including Pfizer-BioNTech, Moderna, and Novavax, which received FDA authorization in August. The Moderna vaccine, known as Spikevax, is expected to be available soon at major retailers such as RiteAid, Costco, CVS, Walgreens, and Walmart. Studies indicate that Novavax, a protein-based vaccine, has fewer side effects compared to mRNA vaccines like Moderna. Novavax reduces viral load by 600x, while Moderna reduces it by 100x.
View original story
Similar markets
Novavax • 25%
Moderna • 25%
Pfizer • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Novavax • 25%
Other • 25%
Pfizer has the largest market share • 25%
Moderna has the largest market share • 25%
Novavax has the largest market share • 25%
Other companies have the largest market share • 25%
Pfizer (KP.2) • 25%
Moderna (KP.2) • 25%
Novavax (JN.1) • 25%
All equally effective • 25%
Pfizer is perceived as most effective • 25%
Moderna is perceived as most effective • 25%
Novavax is perceived as most effective • 25%
No clear leader in perception • 25%
Pfizer exceeds expectations • 25%
Moderna exceeds expectations • 25%
Both exceed expectations • 25%
Neither exceed expectations • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Very Effective (>90%) • 25%
Effective (70-90%) • 25%
Moderately Effective (50-70%) • 25%
Ineffective (<50%) • 25%
High (>70%) • 25%
Moderate (50-70%) • 25%
Low (30-50%) • 25%
Very Low (<30%) • 25%
